Welcome to our dedicated page for Angiodynamics SEC filings (Ticker: ANGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AngioDynamics, Inc. (NASDAQ: ANGO) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a medical technology company listed on the NASDAQ Global Select Market, AngioDynamics files periodic reports, proxy statements, and current reports that describe its business, governance, and financial condition.
Recent Form 8‑K filings include disclosures about quarterly and annual financial results, along with references to press releases and investor presentation slides that discuss Med Tech and Med Device performance, net sales, and the use of non‑GAAP measures such as adjusted EBITDA. Other 8‑K filings cover shareholder meeting outcomes, including voting results on director elections, auditor ratification, and advisory votes on executive compensation.
The company’s Definitive Proxy Statement (DEF 14A) provides detailed information on corporate governance, executive compensation, and its strategic organization into Med Tech and Med Device platforms. In that filing, AngioDynamics explains that Med Tech comprises high‑growth platforms such as the Auryon Atherectomy laser, Mechanical Thrombectomy products (AngioVac and AlphaVac), and NanoKnife irreversible electroporation products, while Med Device includes angiographic catheters, EVLT products, port products, and other oncology products.
On Stock Titan, investors can use AI‑powered tools to quickly interpret these filings. AI summaries highlight key points from lengthy documents, helping users understand topics such as voting results, segment structure, and the context behind reported financial metrics. Real‑time updates from EDGAR ensure that new 8‑K, 10‑K, 10‑Q, proxy, and related filings are available as soon as they are posted, while insider and governance‑related disclosures can be reviewed alongside financial and strategic information.
AngioDynamics, Inc. received an amended Schedule 13G/A from Divisadero Street Capital Management and related entities, along with William Zolezzi, reporting a very small passive position in its common stock. The group reports beneficial ownership of 4,576 shares, representing 0.01% of AngioDynamics’ outstanding common stock.
The filing shows no sole voting or dispositive power over the shares; all reported power is shared among the reporting persons. All of the securities are directly owned by advisory clients of Divisadero Street Capital Management, and each reporting person disclaims beneficial ownership beyond any pecuniary interest.
The group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics, and that overall ownership remains at or below 5% of the class.
Systematic Financial Management filed a Schedule 13G reporting a passive ownership stake in AngioDynamics Inc. common stock. The firm beneficially owns 2,508,295 shares, representing 6.05% of the outstanding common stock, with sole voting power over 1,478,345 shares and sole dispositive power over all 2,508,295 shares.
The filing states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of AngioDynamics. The reported holdings relate to AngioDynamics common stock with CUSIP 03475V101.
Kevin Kotler has filed a Schedule 13G reporting beneficial ownership of 2,421,526 shares of AngioDynamics, Inc. common stock, representing 5.9% of the class as of 01/06/2026. He holds sole voting and dispositive power over these shares and reports the stake as passive, not for influencing control.
The filing notes that 313,495 shares are owned in his individual capacity, while the remainder is held in accounts he manages. He also formally disclaims beneficial ownership beyond his pecuniary interest in the reported securities.
AngioDynamics outlined a planned leadership transition and retention program for senior executives. President and CEO James C. Clemmer signed a Transition and Retirement Agreement under which he will continue as CEO until a successor is appointed or until November 30, 2026, with possible month‑to‑month extensions by mutual agreement. His existing stock options and service-based restricted stock units will continue to vest until his service as a consultant or director ends, after which they immediately vest, while performance-based restricted stock units may still vest according to their original terms. The board also approved retention agreements for the executive leadership team: key named executive officers are eligible for cash retention awards equal to 150% of base salary and others for 50% of base salary, if they remain employed until the earlier of six months after the new CEO starts or June 1, 2027.
AngioDynamics, Inc. filed a current report after its President and CEO, James Clemmer, presented at the J.P. Morgan 44th Annual Healthcare Conference on January 14, 2026. The company has made the conference presentation slides available as Exhibit 99.1, furnishing them for informational purposes.
The report clarifies that these slides are furnished rather than filed, meaning they are not subject to certain liability provisions and are not automatically incorporated into other securities filings. It also includes a detailed caution about forward-looking statements, noting that expectations about strategy, products, financial position and growth are subject to numerous risks, including regulatory actions, economic conditions, competition, supply chain challenges and factors described in prior AngioDynamics SEC reports.
AngioDynamics, Inc. received an updated large-shareholder disclosure showing that investment entities affiliated with Millennium reported modest, passive stakes in its common stock. Integrated Core Strategies (US) LLC reported beneficial ownership of 551,565 shares, representing 1.3% of AngioDynamics’ common stock. Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each reported beneficial ownership of 842,548 shares, or 2.0% of the outstanding common stock, as of the event date of 12/31/2025. The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of AngioDynamics.
AngioDynamics, Inc. reported stockholder voting results. Shareholders elected two directors: James C. Clemmer received 29,634,152 votes for and 800,454 withheld, with 5,462,943 broker non-votes; Michael E. Tarnoff, MD received 29,245,896 votes for and 1,188,710 withheld, with 5,462,943 broker non-votes.
Stockholders also approved two additional items. One item received 35,727,186 votes for, 156,899 against, and 13,464 abstentions; there were no broker non-votes for this item. Another item received 28,357,782 votes for, 2,057,982 against, 18,842 abstentions, and 5,462,943 broker non-votes.
AngioDynamics (ANGO) reported an insider open‑market purchase. On 10/21/2025, an officer serving as SVP, Chief Legal Officer bought 10,000 shares of common stock, coded “P” for purchase. The weighted average price was $11.81, with trades executed between $11.71 and $11.90. After this transaction, the reporting person beneficially owned 93,597 shares, held directly. The filing notes the weighted‑average pricing and that detailed trade‑by‑trade data within the price range is available upon request.
AngioDynamics, Inc. filed a Form S-8 to register 4,700,000 shares of common stock for issuance under its 2020 Equity Incentive Plan, as approved by shareholders on November 14, 2023 and November 12, 2024.
The filing also includes a Reoffer Prospectus covering the potential resale, from time to time, of up to 2,529,068 shares by certain employees and officers who acquired awards under the plan. The company will receive no proceeds from sales by the selling stockholders, while bearing registration expenses. AngioDynamics’ common stock trades on Nasdaq as “ANGO,” and the last reported sale price was $11.82 per share on October 20, 2025.
Shares outstanding were 41,076,119 as of September 18, 2025; this is a baseline figure, not the amount being registered or resold.
AngioDynamics (ANGO) reported insider activity by its EVP and CFO. A Form 4 shows a purchase of 890 shares of common stock on 10/13/2025 at a price of $11.16 per share, coded “P” for a purchase.
Following the transaction, the reporting person beneficially owns 256,629 shares, held directly. The filing indicates the role as EVP and CFO and confirms the report was filed by one reporting person.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
